12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Custirsen sodium: Phase III started

OncoGenex began the open-label, international Phase III AFFINITY trial to compare custirsen plus Jevtana cabazitaxel and prednisone vs. Jevtana plus prednisone in about 630 CRPC patients who progressed after first-line treatment with docetaxel. OncoGenex and partner Teva are also evaluating docetaxel/prednisone...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >